The Institute for Clinical and Economic Review (ICER) has released a draft report evaluating the evidence supporting the use of 3 biologic drugs for osteoporosis.
The report evaluated abaloparatide, which was recently approved by the FDA; romosuzumab, which is currently being reviewed by the FDA; and teriparatide, which was approved over 15 years ago. The 3 biologic drugs are all anabolic, meaning that they build bone; the other agents approved for osteoporosis are antiresorptive, as they prevent the bone from breaking down. The ICER report compared the 3 anabolic agents to one another, to no therapy, and to intravenous zoledronic acid, which is a commonly used antiresorptive.
As the foremost goal of osteoporosis treatment is to prevent fractures, that was the primary outcome measured in the ICER report, but it also took into account other outcomes, including quality of life, side effects, pain, and bone density. Additionally, the report modeled the long-term cost-effectiveness and potential budget impact of each drug.
Following a thorough review of the available clinical evidence, the report indicated that the anabolic drugs, particularly abaloparatide, were more effective at preventing vertebral fractures compared with no therapy. However, there were no significant differences in fracture occurrence when comparing the agents to each other or to zoledronic acid. Therefore, the researchers found the evidence of net health benefit for each of the 3 drugs to be promising but inconclusive compared with zoledronic acid, and “judged with moderate certainty that the anabolic agents provided a small or substantial net health benefit compared with no therapy.”
The report states that each of the 3 biologic therapies resulted in increased life-years and quality-adjusted life years (QALYs), but also higher costs, compared with zoledronic acid. “The cost per additional QALY was estimated to be above $150,000 per QALY for each anabolic agent, assuming parity pricing with teriparatide for romosozumab and a 40% and 27% discount on prices of teriparatide and abaloparatide, respectively,” it wrote.
Furthermore, “budget impact analyses for abaloparatide and romosozumab indicate that use of both agents in place of teriparatide+zoledronic acid are not likely to generate access or affordability alerts.”
According to a press release announcing the newly published report, ICER will be accepting public comments on the report until May 31. At the end of June, the report will be the subject of a meeting of the California Technology Assessment Forum, which will “publicly deliberate the evidence and vote on key questions raised in the report, and an expert policy roundtable will discuss recommendations to apply the evidence to policy and practice.”
Abaloparatide is sold as Tymlos by Radius Health, while teriparatide is sold as Forteo by Eli Lilly. Romosozumab is manufactured by Amgen and UCB, and should receive a decision on its approval from the FDA by this July.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.